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Abstract 
Objective  
To examine the association between Fatty Acid Binding Protein 4 (FABP4) and pre-
eclampsia risk in women with type 1 diabetes.  
Research Design and Methods 
Serum FABP4 was measured in 710 women from the DAPIT study in early 
pregnancy and in the second trimester (median 14 and 26 weeks gestation, 
respectively). 
Results 
FABP4 was significantly elevated in early pregnancy (geometric mean [interquartile 
range]: 15.8ng/ml [11.6-21.4] vs. 12.7ng/ml [9.6-17]; P<0.001) and the second 
trimester (18.8ng/ml [13.6-25.8] vs. 14.6ng/ml [10.8-19.7]; P<0.001) in women who 
later developed pre-eclampsia. Elevated second trimester FABP4 was independently 
associated with pre-eclampsia (OR 2.87 (95%CI 1.24, 6.68), P=0.03). Addition of 
FABP4 to established risk factors significantly improved Net Reclassification 
Improvement at both time-points and Integrated Discrimination Improvement in the 
second trimester.  
Conclusions 
Increased second trimester FABP4 independently predicted pre-eclampsia and 
significantly improved reclassification and discrimination. FABP4 shows potential as 
a novel biomarker for pre-eclampsia prediction in women with type 1 diabetes. 
Word Count: 153 including subheadings (limit 150) 
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Introduction 
Pre-eclampsia, defined as new onset hypertension and proteinuria occurring after 20 
weeks gestation, is associated with significant perinatal morbidity and mortality(1, 2). 
Women with type 1 diabetes are 2 to 4 more times more likely develop pre-
eclampsia than the background population(3, 4).  
Fatty Acid Binding Protein 4 (FABP4), or adipocyte fatty acid binding protein, is an 
intracellular lipid chaperone involved in co-ordination of lipid transportation(5). 
FABP4 is expressed mainly in adipocytes and can be released into the circulation(6). 
In the non-pregnant state FABP4 is associated with known pre-eclampsia risk 
factors: obesity, hypertension and diabetes(6, 7).  
Several studies have reported elevated FABP4 in women with pre-eclampsia(8, 9) or 
who later developed pre-eclampsia(10), compared to those who did not, although all 
studies excluded women with diabetes. 
Our objective was to examine the role of FABP4 as a potential biomarker for pre-
eclampsia alone, and in tandem with established clinical risk factors, in women with 
type 1 diabetes.  
Research design and Methods 
The population comprised 710 of the 762 women from the Diabetes and Pre-
eclampsia Intervention Trial (DAPIT), a randomized multicenter double-blind 
placebo-controlled trial investigating vitamin C and E supplementation and risk of 
pre-eclampsia in women with type 1 diabetes(11). Pre-eclampsia, the primary 
endpoint, was defined using International guidelines(1, 12).  Women provided written 
3 
 
informed consent.  West-Midlands Multicenter Research Ethics Committee approved 
the study (MREC 02/7/016).  
Blood samples were collected at randomization (8-22 weeks; median 14 weeks) and 
in the second trimester (median 26 weeks). Serum samples were batch-analyzed, 
blind to pre-eclampsia status, using a commercially available ELISA (Biovendor, 
Modrice, Czech Republic). Inter-assay and intra-assay CVs were 8.3% and 3.8%, 
respectively.  
Intervention and control groups were analyzed together as supplementation did not 
reduce pre-eclampsia risk (risk ratio: 0.81; 95% CI: 0.59, 1.12, P=0.20)(11); FABP4 
levels were not different between groups, and the effect of supplementation on pre-
eclampsia risk did not depend on FABP4. 
Statistical analysis 
FABP4 concentrations were positively skewed and therefore logarithmically 
transformed. Values are reported as geometric mean and interquartile range (IQR). 
Chi-squared ( 2) and independent samples t-tests were used for group comparisons. 
Logistic regression analysis investigated the association between FABP4 and pre-
eclampsia before and after adjusting for the following risk factors: age, BMI, 
gestational age, blood pressure, parity, duration of diabetes, smoking status, history 
of pre-eclampsia, HbA1c, renal status, and DAPIT treatment group. The area under 
the receiver operating characteristic curve (AUROC) was used to assess the 
predictive value of FABP4 for pre-eclampsia(13). Integrated Discrimination 
Improvement (IDI) and Net Reclassification Improvement (NRI) indices were 
calculated to determine the clinical utility of the addition of FABP4 to established risk 
factors and the ability of FABP4 to improve pre-eclampsia prediction (for calculation 
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AUROC, NRI and IDI, see Supplementary Data)(14). Statistical analysis was 
performed using SPSS version 20 (IBM Corp., Armonk, NY), Stata release 14 
(StataCorp, College Station, TX) and the Hmisc package in R version 3.1.3 (R Core 
Team, Vienna, Austria).  
Results 
Serum from one or both time-points was available for 710 women, of whom 120 
(17%) developed pre-eclampsia (for maternal and clinical characteristics see 
Supplementary Table 1).  
FABP4 levels at randomization (median 14 weeks) and 26 weeks were significantly 
higher in women who later developed pre-eclampsia compared with those who did 
not (Table 1). Of the 319 women with blood samples at 13 weeks or less, FABP4 
levels were elevated in those who later developed pre-eclampsia compared to those 
who did not (P=0.02).  
For each doubling of serum FABP4, adjusted risk of pre-eclampsia increased by 
40% (OR 1.4 (95%CI 1.0, 2.0), P=0.031) and 60% (1.6 (1.1, 2.3), P=0.017) at 14 and 
26 weeks, respectively.  The independent ability of FABP4 to predict preeclampsia, 
in relation to quarters of FABP4 in combination with established risk factors, is 
shown in Supplementary Table 2.  In the second trimester, the highest quarter of 
FABP4 was a significant independent predictor of pre-eclampsia compared with the 
lowest (OR 2.87; 95%CI 1.24, 6.68), P=0.03).  
AUROCs for FABP4 alone were 0.622 and 0.646 at 14 and 26 weeks, respectively 
(Table 1). When FABP4 was added to the model containing established risk factors, 
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AUROCs were 0.801 and 0.825 at 14 and 26 weeks, respectively (both non-
significant from established risk factors alone).  
The NRI statistic showed that the addition of FABP4 to established risk factors 
significantly increased correct reclassification of cases and non-cases at both 14 and 
26 weeks. The IDI statistic showed that FABP4 significantly increased discrimination 
between cases and non-cases in the second trimester (Table 1).  
Conclusions 
We believe this is the first study to date to investigate FABP4 levels in relation to 
development of pre-eclampsia and to investigate its clinical utility in pregnant women 
with type 1 diabetes. Maternal FABP4 levels were significantly elevated in women 
who later developed pre-eclampsia compared with those who did not both at 14 and 
26 weeks gestation. Furthermore, the addition of FABP4 to established risk factors 
improved the reclassification index at both time-points and discrimination index in the 
second trimester.   
Only one previous study has measured FABP4 prior to the onset of pre-eclampsia. 
In line with our findings, Scifres and colleagues(10) reported significantly elevated 
FABP4 before 13 weeks and at 26 weeks gestation in non-diabetic women who later 
developed pre-eclampsia.  
FAPB4 may play a role in pre-eclampsia development. Shangguan and 
colleagues(9) reported increased third trimester FAPB4 levels in women with pre-
eclampsia compared with healthy pregnant and non-pregnant women, suggesting no 
effect of pregnancy on FABP4, thus implicating FABP4 in pre-eclampsia 
development.    
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This study explores the both predictive properties and clinical utility of FABP4 in 
relation to pre-eclampsia in women with type 1 diabetes. FABP4 remained 
significantly associated with pre-eclampsia after controlling for established risk 
factors. FABP4, when added to established risk factors, did not significantly increase 
the AUROC. However, the NRI and IDI indices, which are proposed as superior 
methods to determine clinical utility of a biomarker(14), showed that FABP4, in 
addition to clinical risk factors, improved the prediction of pre-eclampsia. This was 
significant for NRI at 14 weeks and for both NRI and IDI at 26 weeks.  
The strengths of this study include the study size, with DAPIT being the largest 
prospective dataset reported of thoroughly characterized women with type 1 
diabetes, together with the strict definition of pre-eclampsia, as each potential case 
was reviewed independently by three clinicians(11, 15). In addition, women with 
essential hypertension or any existing renal disease were included, making our study 
more representative of the typical population.  The study has the limitation that trial 
participants may not be entirely representative of all pregnant women with type 1 
diabetes, as they were self-selecting. Randomization samples also represented a 
range of gestational ages from 8 weeks to 22 weeks.  
In summary, we believe this is the first study to investigate FABP4 in relation to the 
development of pre-eclampsia in pregnant women with type 1 diabetes. FABP4 
levels in both the first and second trimester were significantly associated with the 
development of pre-eclampsia. Elevated second trimester FABP4 independently 
predicted pre-eclampsia, significantly improving reclassification and discrimination. 
While further studies are now needed to replicate these findings, our data suggest 
that FABP4 shows potential as a novel biomarker for pre-eclampsia prediction in 
women with type 1 diabetes. 
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Table 1:  
Serum FABP4 concentrations at randomization and in the second trimester, with area under the receiver operating characteristic curve 
(AUROC), Net Reclassification Improvement (NRI) and Integrated Discrimination Improvement (IDI) analyses 
 Maternal serum FABP4 concentration* 
(ng/ml) 
Area under receiver operating characteristic curve (AUROC) 
NRI (P) IDI (P) 
Pre-eclampsia No pre-eclampsia 
FABP4 alone Established risk 
factors without 
FABP4 
Established risk 
factors with 
FABP4 
Incremental 
area (P)† 
Randomization 15.8 (11.6-21.4) 12.7 (9.6-17.0) 0.622 0.793 0.801 0.008 
(0.17) 
0.306 
(0.003) 
0.009 
(0.11) 
Second trimester 18.8 (13.6-25.8) 14.6 (10.8-19.7) 0.648 0.819 0.825 0.006 
(0.34) 
0.251 
(0.02) 
0.012 
(0.048) 
*Reported as geometric mean and interquartile range 
† Comparison of AUROCs: Established risk factors without FABP4 vs Established risk factors with FABP4 
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